Skip to content

Sugammadex reversal of deep rocuronium-Induced neuromuscular blockade in the laparoscopic gastric cancer radical surgery of elderly patients: a radomised controlled trial

Sugammadex reversal of deep rocuronium-Induced neuromuscular blockade in the laparoscopic gastric cancer radical surgery of elderly patients: a radomised controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022926
Enrollment
Unknown
Registered
2019-05-03
Start date
2019-05-08
Completion date
Unknown
Last updated
2019-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic radical gastric cancer

Interventions

1:Low-pressure pneumoperitoneum+deep rocuronium-Induced neuromuscular blockade
2:standard-pressure pneumoperitoneum(12-15mmHg)+deep rocuronium-Induced neuromuscular blockade
3:standard-pressure pneumoperitoneum(12-15mmHg)+standard rocuronium-Induced neuromuscular blockade

Sponsors

Ningbo First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Aged 60 years to 85 years; (2) The usual residence is less than 2500 meters above sea level; (3) Alternative radical laparoscopic gastric cancer.

Exclusion criteria

Exclusion criteria: (1) ASA IV or V or VI; (2) Severe blood system disease or coagulation dysfunction clearly diagnosed in clinical practice; (3) Patients with preoperative chemotherapy; (4) Patients with renal insufficiency(glomerular filtration rate & lt; 30 mL/min); (5) Patients with liver function impairment(AST, ALT is more than 1.5 times normal); (7) Known or suspected allergies to drugs used during anesthesia,(family) history of neuromuscular diseases,(family) history of malignant hyperthermia; The tumor has metastasized at a distance; (8) Can not cooperate with research for any reason, such as the following situations: language understanding, mental illness, etc.. (9) Taking other experimental drugs or participating in other clinical trials within 3 months before being selected for the study. (10) The researcher believes that it is not appropriate to include this experiment.

Design outcomes

Primary

MeasureTime frame
L-SRS surgical condition score;

Secondary

MeasureTime frame
TNF-a?IL- 6 concentration;BP?HR?SPO2?TOFc??PTC value,SpHb,SPI value;

Countries

China

Contacts

Public ContactChangshun Hang

Ningbo First Hospital

nbhcs1967@163.com+86 13957882779

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026